https://baystatetimes.com/article/908547758-peo4you-integrates-medical-debt-relief-contributions-into-benefits-consulting-business-model Bay State Times en PressRelease 2026-04-27T21:33:10+00:00 PEO4YOU Integrates Medical Debt Relief Contributions Into Benefits Consulting Business Model https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24842103-peo4you-medical-debt-relief-ini-1200x630.png https://baystatetimes.com/article/907589370-apstron-science-introduces-patent-pending-physiowatch-for-continuous-physiological-monitoring Bay State Times en PressRelease 2026-04-27T17:15:00+00:00 ApsTron Science Introduces Patent-Pending PhysioWatch™ for Continuous Physiological Monitoring https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24839836-physiowatch-tm-532x761.png https://baystatetimes.com/article/908490326-adaptive-sports-new-england-receives-30-000-grant-from-the-hartford Bay State Times en PressRelease 2026-04-27T17:05:19+00:00 Adaptive Sports New England Receives $30,000 Grant From The Hartford https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24841780-new-england-adaptive-sports-4096x3774.jpeg https://baystatetimes.com/article/908468386-varstreet-now-supports-scim-based-user-provisioning-with-microsoft-entra-id Bay State Times en PressRelease 2026-04-27T15:10:52+00:00 VARStreet Now Supports SCIM-Based User Provisioning with Microsoft Entra ID https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/743488-varstreet-logo-2000x2000.jpeg https://baystatetimes.com/article/908356600-respiratory-care-professor-medtech-co-founder-presents-novel-neonate-breathing-technology-at-pas-meeting-in-boston Bay State Times en PressRelease 2026-04-27T11:38:39+00:00 Respiratory Care Professor, MedTech Co-Founder Presents Novel Neonate Breathing Technology at PAS Meeting in Boston https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24201100-brian-walsh-phd-chairman-of-t-1023x1160.jpeg https://baystatetimes.com/article/908551219-elevatebio-to-present-nine-abstracts-showcasing-advancements-across-its-gene-editing-platform-at-the-american-society-of-gene-and-cell-therapy-asgct Bay State Times en PressRelease 2026-04-27T21:00:00+00:00 ElevateBio to Present Nine Abstracts Showcasing Advancements Across its Gene Editing Platform at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting https://ml.globenewswire.com/media/42238eb2-fd1c-4189-bf14-c7026687de5b/small/elevatebiologo-jpg.jpg https://baystatetimes.com/article/908551243-arbor-biotechnologies-to-present-expansion-of-cns-editing-platform-capabilities-at-the-american-society-of-gene-and-cell-therapy-asgct-29th-annual Bay State Times en PressRelease 2026-04-27T21:00:00+00:00 Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting https://ml.globenewswire.com/media/68842426-d5ae-4dd2-800a-89d80ad4b3b7/small/arbor-biotech-logo-web-3-1-jpg.jpg https://baystatetimes.com/article/908543554-tessera-therapeutics-to-present-new-preclinical-data-supporting-in-vivo-program-in-sickle-cell-disease-and-advancements-in-in-vivo-car-t-applications Bay State Times en PressRelease 2026-04-27T20:46:54+00:00 Tessera Therapeutics to Present New Preclinical Data Supporting In Vivo Program in Sickle Cell Disease and Advancements in In Vivo CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting https://ml.globenewswire.com/media/f24875fb-efec-43e6-8b98-2da3edea398a/small/picture1-jpg.jpg https://baystatetimes.com/article/908543724-ses-lawsuit-ses-ai-corp-sued-for-securities-fraud-investors-should-contact-block-leviton-to-possibly-recover-losses Bay State Times en PressRelease 2026-04-27T20:44:36+00:00 SES LAWSUIT: SES AI Corp. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://baystatetimes.com/article/908543546-dyne-therapeutics-announces-upcoming-presentation-highlighting-robust-cns-activity-in-nonhuman-primates-with-its-force-platform-at-2026-asgct-annual Bay State Times en PressRelease 2026-04-27T20:34:05+00:00 Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg https://baystatetimes.com/article/908543347-voyager-iv-delivered-cns-gene-therapies-featured-in-multiple-presentations-at-asgct-2026-including-late-breaker-on-tau-targeted-vy1706-for Bay State Times en PressRelease 2026-04-27T20:31:00+00:00 Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease https://ml.globenewswire.com/media/f775f55a-83dd-4b38-bf92-bb9b588522bd/small/voyager-logos-square-logo-light-png.png https://baystatetimes.com/article/908543485-editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific Bay State Times en PressRelease 2026-04-27T20:31:00+00:00 Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences https://ml.globenewswire.com/media/03686b66-5cbc-40b5-9dfa-be0e7858ac97/small/editas-logo-small-1-jpg.jpg https://baystatetimes.com/article/908543385-rgenta-therapeutics-announces-two-oral-presentations-highlighting-proprietary-rswitch-technology-at-the-american-society-of-gene-and-cell-therapy Bay State Times en PressRelease 2026-04-27T20:30:00+00:00 Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting https://ml.globenewswire.com/media/de2f6450-22c4-4c16-b785-04cea917de03/small/rgenta-logo-fullcolor-print-1-png.png https://baystatetimes.com/article/908543418-tscan-therapeutics-announces-upcoming-presentation-at-the-american-society-of-gene-and-cell-therapy-29th-annual-meeting Bay State Times en PressRelease 2026-04-27T20:30:00+00:00 TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting https://ml.globenewswire.com/media/d8d2632e-0ce4-4ed2-940e-22a1c599d43f/small/tscan-logo-png.png https://baystatetimes.com/article/908543483-beta-bionics-to-present-at-the-bank-of-america-securities-health-care-conference Bay State Times en PressRelease 2026-04-27T20:25:00+00:00 Beta Bionics to Present at the Bank of America Securities Health Care Conference https://ml.globenewswire.com/media/88df4d95-789c-467a-8481-f67e19e1adfa/small/beta-bionics-logo-2color-1200-png.png https://baystatetimes.com/article/908535777-northeast-bank-reports-third-quarter-results-and-declares-dividend Bay State Times en PressRelease 2026-04-27T20:16:00+00:00 Northeast Bank Reports Third Quarter Results and Declares Dividend https://ml.globenewswire.com/media/ec44d25b-c247-4d5d-9264-10fb03e30aa8/small/nebank-cmyk-transparent-sm-png.png https://baystatetimes.com/article/908535446-intellia-announces-proposed-public-offering-of-common-stock Bay State Times en PressRelease 2026-04-27T20:01:00+00:00 Intellia Announces Proposed Public Offering of Common Stock https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://baystatetimes.com/article/908519740-poet-technologies-inc-investors-should-contact-block-leviton-to-find-out-how-they-might-recover-losses-through-the-firm-s-investigation Bay State Times en PressRelease 2026-04-27T18:46:10+00:00 POET Technologies Inc. Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://baystatetimes.com/article/908505217-ai-disruption-in-lung-cancer-therapeutics-set-to-transform-treatment-paradigms-as-billion-dollar-investments-drive-innovation Bay State Times en PressRelease 2026-04-27T17:36:49+00:00 AI Disruption in Lung Cancer Therapeutics Set to Transform Treatment Paradigms as Billion-Dollar Investments Drive Innovation https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://baystatetimes.com/article/908368739-choosing-a-global-high-purity-fluorinated-building-blocks-vendor-for-modern-labs-aifchem Bay State Times en PressRelease 2026-04-27T05:08:32+00:00 Choosing a Global High-Purity Fluorinated Building Blocks Vendor for Modern Labs: AiFChem https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24841275-high-purity-fluorinated-buildin-1116x746.png https://baystatetimes.com/article/908368419-strategic-advantages-of-partnering-with-a-global-high-purity-heterocyclic-building-blocks-supplier-aifchem Bay State Times en PressRelease 2026-04-27T05:08:09+00:00 Strategic Advantages of Partnering with a Global High-Purity Heterocyclic Building Blocks Supplier: AiFChem https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24841273-global-high-purity-heterocyclic-757x600.png https://baystatetimes.com/article/908485953-macom-to-enter-into-agreements-to-further-strengthen-supply-chain Bay State Times en PressRelease 2026-04-27T16:00:29+00:00 MACOM to Enter into Agreements to Further Strengthen Supply Chain https://ml.globenewswire.com/media/a79ab6f0-6800-4764-913c-aa1e39eb512e/small/macomwrdmrkrgbtag-4-png.png https://baystatetimes.com/article/908452226-addgene-reinforces-its-expanding-role-in-research-with-new-brand Bay State Times en PressRelease 2026-04-27T13:30:00+00:00 Addgene Reinforces Its Expanding Role in Research with New Brand https://ml.globenewswire.com/media/e4b4a6b0-9eac-49c5-852f-53fce9ecf258/small/addgene-logo-blue-png.png https://baystatetimes.com/article/908452232-signnow-launches-docgen-api-to-automate-business-document-creation-and-close-the-gap-between-data-and-signature Bay State Times en PressRelease 2026-04-27T13:30:00+00:00 SignNow Launches Docgen API to Automate Business Document Creation and Close the Gap Between Data and Signature https://ml.globenewswire.com/media/aab78b76-7606-4e1a-ac9e-3519885f79d4/medium/docgen-api-by-signnow.png https://baystatetimes.com/article/908452251-harvard-apparatus-regenerative-technology-announces-first-patient-treated-with-cellspan-esophageal-implant-at-mayo-clinic Bay State Times en PressRelease 2026-04-27T13:30:00+00:00 Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic https://ml.globenewswire.com/media/686ae558-8768-4fc3-bdce-87ae3b318dd6/small/hrgn-logo-jpg.jpg https://baystatetimes.com/article/908447950-alpha-tau-announces-presentation-of-pancreatic-cancer-data-at-upcoming-asco-annual-meeting-showcasing-combined-results-from-three-alpha-dart Bay State Times en PressRelease 2026-04-27T13:01:00+00:00 Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://baystatetimes.com/article/908443320-akari-therapeutics-secures-australian-patent-approval-further-expanding-global-protection-of-its-proprietary-ph1-rna-splicing-modulator-adc-payload Bay State Times en PressRelease 2026-04-27T12:35:00+00:00 Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://baystatetimes.com/article/908438912-cerence-to-announce-fiscal-second-quarter-results-on-may-7-2026 Bay State Times en PressRelease 2026-04-27T12:00:00+00:00 Cerence to Announce Fiscal Second Quarter Results on May 7, 2026 https://ml.globenewswire.com/media/873690ee-866c-4dea-9808-10aecc02890f/small/cerence-ai-logo-full-color-h-1-png.png https://baystatetimes.com/article/908439016-avalyn-strengthens-leadership-team-to-support-long-term-growth-with-appointments-of-industry-leaders-adam-golden-and-frank-salisbury Bay State Times en PressRelease 2026-04-27T12:00:00+00:00 Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury https://ml.globenewswire.com/media/84d7bff4-ce17-433b-8c71-aa20c30f9f43/small/avalyn-logo-final-png.png https://baystatetimes.com/article/908439020-replimune-to-present-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting Bay State Times en PressRelease 2026-04-27T12:00:00+00:00 Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting https://ml.globenewswire.com/media/NzU1N2M2NzEtNmRkNS00ODQ0LTg0YmQtZTVjMDZhZTRlNjQ1LTExMjIxMDEtMjAyNi0wNC0yNy1lbg==/tiny/Replimune-Inc-.png https://baystatetimes.com/article/908434376-tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-randomized-phase-2-3-study-in-patients-with-biliary-tract-cancer Bay State Times en PressRelease 2026-04-27T11:30:00+00:00 Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://baystatetimes.com/article/908434378-nima-s-next-gen-portable-gluten-sensor-wins-gold-stevie-award-for-achievement-in-product-innovation Bay State Times en PressRelease 2026-04-27T11:30:00+00:00 NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation https://ml.globenewswire.com/media/a025c49c-a270-4041-92e3-76d50d9bc27f/medium/nima-is-the-2026-gold-stevie-award-winner.png https://baystatetimes.com/article/908429883-fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first-quarter-2026 Bay State Times en PressRelease 2026-04-27T11:00:00+00:00 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://baystatetimes.com/article/908429920-sionna-therapeutics-completes-enrollment-in-precision-cf-phase-2a-trial-evaluating-nbd1-stabilizer-sion-719-added-to-standard-of-care-in Bay State Times en PressRelease 2026-04-27T11:00:00+00:00 Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png https://baystatetimes.com/article/908430156-intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioedema-marking-a-global-first-for-in-vivo-gene-editing Bay State Times en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://baystatetimes.com/article/908430163-intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment Bay State Times en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://baystatetimes.com/article/908430198-ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences Bay State Times en PressRelease 2026-04-27T11:00:00+00:00 Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://baystatetimes.com/article/908425638-fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors Bay State Times en PressRelease 2026-04-27T10:55:00+00:00 Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://baystatetimes.com/article/908418144-relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-supportive-of-further-development-in-frontline Bay State Times en PressRelease 2026-04-27T10:00:00+00:00 Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer https://ml.globenewswire.com/media/079b6db5-ce81-4a81-9cde-d97f86c569ae/small/logo-banner-small-png.png